transparent gif


Ej inloggad.

Göteborgs universitets publikationer

A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.

Författare och institution:
Dubravka Grdic Eliasson (Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi); Anja Helgeby (-); Karin Schön (Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi); Caroline Nygren (-); Karim El-Bakkouri (-); Walter Fiers (-); Xavier Saelens (-); Karin Bengtsson Lövgren (-); Ida Nyström (-); Nils Y Lycke (Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi)
Publicerad i:
Vaccine, 29 ( 23 ) s. 3951-61
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
Here we demonstrate that by using non-toxic fractions of saponin combined with CTA1-DD we can achieve a safe and above all highly efficacious mucosal adjuvant vector. We optimized the construction, tested the requirements for function and evaluated proof-of-concept in an influenza A virus challenge model. We demonstrated that the CTA1-3M2e-DD/ISCOMS vector provided 100% protection against mortality and greatly reduced morbidity in the mouse model. The immunogenicity of the vector was superior to other vaccine formulations using the ISCOM or CTA1-DD adjuvants alone. The versatility of the vector was best exemplified by the many options to insert, incorporate or admix vaccine antigens with the vector. Furthermore, the CTA1-3M2e-DD/ISCOMS could be kept 1 year at 4°C or as a freeze-dried powder without affecting immunogenicity or adjuvanticity of the vector. Strong serum IgG and mucosal IgA responses were elicited and CD4 T cell responses were greatly enhanced after intranasal administration of the combined vector. Together these findings hold promise for the combined vector as a mucosal vaccine against influenza virus infections including pandemic influenza. The CTA1-DD/ISCOMS technology represents a breakthrough in mucosal vaccine vector design which successfully combines immunomodulation and targeting in a safe and stable particulate formation.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Medicinska grundvetenskaper ->
Immunologi inom det medicinska området
Adjuvants, Immunologic, Animals, Cholera Toxin, administration & dosage, genetics, immunology, Genetic Vectors, administration & dosage, immunology, Humans, ISCOMs, administration & dosage, genetics, immunology, Immunity, Mucosal, Immunization, Influenza A Virus, H1N1 Subtype, immunology, pathogenicity, Influenza A Virus, H3N2 Subtype, immunology, pathogenicity, Influenza Vaccines, administration & dosage, genetics, immunology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Mucous Membrane, immunology, Orthomyxoviridae Infections, immunology, prevention & control, virology, Reassortant Viruses, immunology, pathogenicity, Recombinant Fusion Proteins, administration & dosage, genetics, immunology, Treatment Outcome, Viral Matrix Proteins, administration & dosage, genetics, immunology
Postens nummer:
Posten skapad:
2012-06-12 11:19
Posten ändrad:
2012-06-12 13:51

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007